AGA Family of Websites:

Here’s a new approach to de-prescribing PPIs

Experts share 10 pieces of best practice advice highlighting specific clinical scenarios that call for discontinuing PPIs, and how to approach de-prescribing.
Proton pump inhibitors (PPIs)
Proton pump inhibitors (PPIs)

AGA has released a new Clinical Practice Update providing best practice advice on how to approach de-prescribing proton pump inhibitors (PPI) in ambulatory patients.


  • All patients taking a PPI should have a regular review of the ongoing indications for use and documentation of that indication. This review should be the responsibility of the patient’s primary care provider.
  • All patients without a definitive indication for chronic PPI should be considered for trial of de-prescribing.
  • Most patients with an indication for chronic PPI use who take twice-daily dosing should be considered for step down to once-daily PPI.
  • Patients with complicated gastroesophageal reflux disease, such as those with a history of severe erosive esophagitis, esophageal ulcer, or peptic stricture, should generally not be considered for PPI discontinuation.
  • Patients with known Barrett’s esophagus, eosinophilic esophagitis, or idiopathic pulmonary fibrosis should generally not be considered for a trial of de-prescribing.
  • PPI users should be assessed for upper gastrointestinal bleeding risk using an evidence-based strategy before de-prescribing.
  • Patients at high risk for upper gastrointestinal bleeding should not be considered for PPI de-prescribing.
  • Patients who discontinue long-term PPI therapy should be advised that they may develop transient upper gastrointestinal symptoms due to rebound acid hypersecretion.
  • When de-prescribing PPIs, either dose tapering, or abrupt discontinuation can be considered.
  • The decision to discontinue PPIs should be based solely on the lack of an indication for PPI use, and not because of concern for PAAEs. The presence of a PAAE or a history of a PAAE in a current PPI user is not an independent indication for PPI withdrawal. Similarly, the presence of underlying risk factors for the development of an adverse event associated with PPI use should also not be an independent indication for PPI withdrawal.


Read the complete AGA Clinical Practice Update on De-Prescribing on Proton Pump Inhibitors Expert Review, published in the April issue of Gastroenterology and authored by Drs. Laura Targownik, Deborah A. Fisher and Sameer Saini.

AGA Clinical Guidance
Evidence-based recommendations.

AGA clinical guidance

Find the latest evidence-based recommendations for treating your patients.